Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Atea Pharmaceuticals

Johnson & Johnson

Moderna

Pfizer

Sorrento Therapeutics Inc

Vaxart

You may have thought the moment of relevancy for these biotech stocks was over, but the Delta variant has changed their prospects. The post 7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught appeared first on InvestorPlace.

7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught

FDA likely to decide on Merck's (MRK) sBLA for Keytruda as an adjuvant therapy in certain patients with RCC on Dec 10 and in certain patients with MSI-H/dMMR advanced endometrial carcinoma on Mar 28, 2022.

Merck's (MRK) Two Keytruda sBLAs Get Accepted by the FDA

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progr

FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck's anti-PD-1 therapy, for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy (surgical removal of a kidney), or following n

FDA Grants Priority Review to Merck's Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

AbbVie

Abbott Labs

Anthem

Bristol-Myers

Cigna

Medtronic

PIMCO Corporate & Income Opportunity Fund

Cohen & Steers Reit And Preferred Income Fund Inc

abrdn Life Sciences Investors 

Thermo Fisher Scientific

UnitedHealth Group

A monthly income stream provides a lot of flexibility for the income investor. Monthly dividends makes DCA work even better.

3 Big Dividends, Paying Monthly, For Your Retirement Basea

MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belen Garijo on Q2 2021 Results - Earnings Call Transcript

Eli Lilly

Novo Nordisk

Novartis

Roche Holding AG

The Wall Street firm put big drugmakers' R&D programs through five different tests.

Here Are the Winners of Cowen's Big Pharma R&D Showdown

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Prolonged RFS Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716

Merck's KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial

Merck KGaA raised its outlook after posting forecast-beating second quarter profits on Thursday, boosted by demand for its lab gear and supplies from pharma companies making treatments and vaccines against the coronavirus.

Merck KGaA raises outlook after forecast-beating Q2 profit

Takeda Pharmaceutical

It has become the proverbial broken record. Every time it seems like yields on government securities will start trending higher, they roll over again.

4 Big Pharma Dividend Stocks to Buy as Yields Near 2021 Lows

Apple

Accenture Plc

Automatic Data Processing

CME Group

Costco

Cisco Systems

General Dynamics

Home Depot

Honeywell

Intel

Lockheed Martin

Mastercard

Microsoft

NIKE

PepsiCo

Procter & Gamble

Stryker

Texas Instruments

Union Pacific

Visa

Walmart

This article updates one published by David Van Knapp in June 2020.

The Highest Quality Dividend Growth Stocks

Colgate-Palmolive

Enterprise Products Partners

Gladstone Investment

Interpublic Group of Companies

LTC Properties

Main Street Capital

MetLife

People's United Financial

iShares Preferred and Income Securities ETF 

Prudential Financial

Shaw Communications

STAG Industrial

Unum

Verizon

Exxon Mobil

From May to December 2020, Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. Those five "outstanding dividend" articles revealed 56 equities. Kiplinger article titles were, 'Dividend15: Our Favorites'; '15 Super-Safe Dividends'; '7 Durable Distributions'; '13 100+Year Dividends'; '11 Monthly-Pay Stocks/Funds.'

Kiplinger Outstanding August Dividend Dogs Feature 9 Primed To Buy

Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?

Amgen

A handful of healthcare giants are some of the few Dow stocks in the red so far today, as federal data underpins the prospects of a continued economic recovery.

Healthcare Stock Sell-Off Keeps the Dow Jones From Reaching Record Levels

Merck & Co., Inc. (MRK) CEO Rob Davis on Q2 2021 Results - Earnings Call Transcript

Merck (MRK) misses Q2 estimates for earnings but beats the same for sales. Stock down in pre-market.

Merck (MRK) Q2 Earnings Miss, Sales Rebound, Stock Slips

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer

Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer

Strong revenue from cancer treatment Keytruda stood out in Merck's results, with analysts highlighting upside to sales estimates for the drug.

Merck Sales Beat Estimates, But the Stock Fell. Here's 1 Reason to Be Bullish.

Merck (MRK) delivered earnings and revenue surprises of 0.77% and 1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Q2 Earnings and Revenues Surpass Estimates

Merck & Co Inc (NYSE: MRK) Q2 sales reached $11.4 billion, +22% Y/Y, missing the consensus of $11.5 billion. Excluding the foreign exchange impact, revenues were up 19%, reflecting ongoing recovery from the COVID-19 pandemic and underlying solid demand.

Merck Stock Falls As Q2 Earnings Lag Wall Street Estimates, Trimmed FY21 Guidance Below Consensus

News for Merck Stock (MRK)